Clinical trials: Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor…
- Trial name
- NCT06520345
- Testing
- 177Lu-TLX591, Enzalutamide, Abiraterone
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 520 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostate Cancer
A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor…
- Trial name
- NCT07567521
- Testing
- Radiopharmaceuticals
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- C Ray Therapeutics
Prostatic Cancer, Castration-Resistant
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617)…
- Trial name
- NCT07047118
- Testing
- JSB462, AAA617
- Where
- 44 sites in United States, Australia and 13 more
- Volunteers
- 138 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Prostate Adenocarcinoma, PSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer
KuPSMALu-trial is an observational study for patients treated with 177LuPSMA-I\&T in Kuopio University Hospital, Finland. Study focuses on efficacy, safety and biomarker research.
- Trial name
- KuPSMALu (NCT06850545)
- Where
- Finland
- Volunteers
- 150 people
- Sponsor
- Kuopio University Hospital
Prostatic Neoplasm
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer…
- Trial name
- PROter (NCT03490838)
- Testing
- 177Lu-PSMA-R2
- Where
- 11 sites in United States, Spain
- Volunteers
- 27 people
- Sponsor
- Advanced Accelerator Applications
Oligometastatic Prostate Cancer (OMPC)
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary…
- Trial name
- PSMA-DC (NCT05939414)
- Testing
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Where
- 144 sites in United States, Argentina and 25 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer (mCRPC)
An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
The purpose of this study is to assess safety of combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI and AAA617 alone in PSMA-positive mCRPC patients who were previously treated and…
- Trial name
- PSMAndARPI (NCT06894511)
- Testing
- AAA617, ARPI: Abiraterone, ARPI: Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）
This is a phase I clinical trial conducted in participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT07660211
- Testing
- 177Lu-PSMA-VG01
- Where
- China
- Volunteers
- 10 people
- Sponsor
- VitsGen Therapeutics Inc.
Prostate Cancer
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
A Phase I/IIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of INR102 injection in patients with prostate cancer.
- Trial name
- NCT06970119
- Testing
- INR102 injection
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd
Prostate Cancer
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen…
- Trial name
- VISION (NCT03511664)
- Testing
- 177Lu-PSMA-617, Best supportive/best standard of care
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 861 people
- Sponsor
- Endocyte
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617)…
- Trial name
- NCT06004661
- Testing
- AAA617, 68Ga-PSMA-11
- Where
- 9 sites in United States, France and 3 more
- Volunteers
- 23 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
- Trial name
- VECTRA-01 (NCT07611110)
- Testing
- Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone
- Where
- 151 sites in United States, Australia and 22 more
- Volunteers
- 670 people
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer (mCRPC)
68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
This is a single-arm, open-label, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, dosimetry, pharmacodynamics, and preliminary efficacy of Gallium [68Ga] PSMA-0057 Injection and Lutetium…
- Trial name
- NCT07310355
- Testing
- 68Ga-PSMA-0057, 177Lu-PSMA-0057
- Volunteers
- 49 people
- Sponsor
- Chengdu StarRay Therapeutics Co., Ltd
Metastatic Castration-Resistant Prostate Cancer
Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
This is a single-arm, open-label study to evaluate the safety, tolerability and preliminary anti-tumor efficacy of SRT-017 radioligand therapy in patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer…
- Trial name
- SRT-017-001 (NCT07798778)
- Testing
- SRT-017
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
- Trial name
- DUAL-NK-PC (NCT07641049)
- Testing
- ETB-DualNK-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
The purpose of this study was to assess the efficacy, safety, tolerability, Pharmacokinetic(s) (PK) and dosimetry of [177Lu]Lu-PSMA-617 when administered in addition to Best Supportive/Best Standard of Care (BSC/BSoC) in Chinese…
- Trial name
- NCT05670106
- Testing
- [177Lu]Lu-PSMA-617, Best supportive/best standard of care (BS/BSOC), 68Ga-PSMA-11
- Where
- 17 sites in China
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after…
- Trial name
- PSMAcTION (NCT06780670)
- Testing
- Investigators choice of SoC, AAA817
- Where
- 93 sites in United States, Australia and 11 more
- Volunteers
- 443 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body.
- Trial name
- NCT04663997
- Testing
- 177Lu-PSMA-617, Docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Canadian Cancer Trials Group
PSMA PET-Positive Castration-Resistant Prostate Cancer
Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer
Evaluating the safety and antitumor efficacy of 177Lu-LNC1011
- Trial name
- NCT06809426
- Testing
- 177Lu-LNC1011
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Affiliated Hospital of Jiangnan University